|Type||Single domain antibody|
|Chemical and physical data|
|Molar mass||27.88 kg/mol|
This drug is developed by Ablynx NV, and is currently in a phase III clinical trial.
It is an anti-von Willebrand factor humanized immunoglobulin. It acts by blocking platelet aggregation to reduce organ injury due to ischemia. Results of the phase II TITAN trial have been reported.
- Statement On A Nonproprietary Name Adopted By The USAN Council - Caplacizumab, American Medical Association.
- World Health Organization (2011). "International Nonproprietary Names for Pharmaceutical Substances (INN). Proposed INN: List 106" (PDF). WHO Drug Information. 25 (4).
- A Trial With Caplacizumab in Patients With Acquired Thrombotic Thrombocytopenic Purpura (HERCULES)
- Immune Drug Tackles Microvascular Thrombosis Disorder. Feb 2016
|This monoclonal antibody-related article is a stub. You can help Wikipedia by expanding it.|